AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
Plasminogen Activator Inhibitor 1Plasminogen Activator Inhibitor 2Plasminogen InactivatorsTissue Plasminogen ActivatorUrokinase-Type Plasminogen ActivatorPlasminogen ActivatorsPlasminogenFibrinolysisReceptors, Urokinase Plasminogen ActivatorFibrinolysinVitronectinFibrinSerpin E2alpha-2-AntiplasminSerine Proteinase InhibitorsGlycoproteinsRNA, MessengerReceptors, Cell SurfaceFibrinolytic AgentsSerpinsHemostasisFibrinogenBlood CoagulationCells, CulturedRecombinant ProteinsFibrin Fibrinogen Degradation ProductsEndothelium, VascularKineticsTumor Cells, CulturedMolecular Sequence DataThrombosisGene Expression RegulationTransforming Growth Factor betaCell LineBlotting, NorthernAntithrombin IIIBase SequenceElectrophoresis, Polyacrylamide GelUmbilical VeinsFibrosarcomaBlood Coagulation FactorsExtracellular MatrixThrombolytic TherapyThrombinLow Density Lipoprotein Receptor-Related Protein-1Protein BindingAmino Acid SequenceBinding SitesProtease NexinsTranscription, GeneticTime FactorsStreptokinaseEnzyme-Linked Immunosorbent AssayGene ExpressionPromoter Regions, GeneticThrombomodulinProtein CThromboplastinAntifibrinolytic AgentsDose-Response Relationship, DrugEnzyme PrecursorsEndotheliumHeparinMolecular WeightMice, Inbred C57BLTransforming Growth Factor beta1Blood Coagulation TestsTransfectionUp-Regulationvon Willebrand FactorCulture Media, ConditionedSignal TransductionCycloheximideTetradecanoylphorbol AcetateTransforming Growth FactorsBlotting, WesternChromogenic CompoundsEnzyme ActivationImmunohistochemistryCell MovementTrypsin Inhibitor, Kunitz SoybeanKringlesIn Situ HybridizationSerine EndopeptidasesTumor Necrosis Factor-alphaHemostatic DisordersFactor VIIAminocaproic AcidPeptide HydrolasesMinkReverse Transcriptase Polymerase Chain ReactionProtease InhibitorsFibroblastsBiological MarkersFibronectinsProtein C InhibitorDNAMice, KnockoutPeptide FragmentsSmad3 Protein
Urokinase plasminogen activatorPAI1ELISA KitDeficiencyVitronectinTissue-typeFibrinolysisProteinsSerine proteaseSerpinTypeInhibitsInducesEndothelialCellsInhibitionProteinMiceAlveolarMoleculeExogenousIndicationsPlateletsMigrationFactorIntrinsicDetectionMeSHPlasmaStabilityHumanDrugsLevelsPatientsPotentialPublications
Urokinase plasminogen activator3
  • In vitro photophysical and biological studies show high intrinsic ability to inhibit the activity of urokinase plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9). (ua.pt)
  • Several 8-substituted 2-naphthamidine-based inhibitors of the serine protease urokinase plasminogen activator (uPA) are described. (rcsb.org)
  • One of the most thoroughly studied systems in relation to its prognostic relevance in patients with breast cancer, is the plasminogen activation system that comprises of, among others, the urokinase Plasminogen Activator (uPA) and its main inhibitor, the Plasminogen Activator Inhibitor-1 (PAI-1). (biomedcentral.com)
PAI18
ELISA Kit1
Deficiency3
Vitronectin5
Tissue-type2
Fibrinolysis4
  • Although aberrant fibrinolysis and plasminogen activator inhibitor 1 (PAI-1) are implicated in acute lung injury, the role of this serpin in the pathogenesis of wood bark smoke (WBS)-induced acute lung injury (SIALI) and its regulation in resident lung cells after exposure to smoke are unclear. (usuhs.edu)
  • 11 ] Henry and colleagues recently demonstrated that ICU-admitted COVID-19 patients had lower levels of circulating plasminogen than non-ICU patients, suggesting an exhaustion of fibrinolysis. (thieme-connect.com)
  • Plasminogen activator inhibitor (PAI)-1 is an inhibitor of fibrinolysis, the physiological process involved in blood clot degradation. (cdc.gov)
  • The decrease in fibrinolysis might be due to an increase in thrombin-activatable fibrinolysis inhibitor and an increase in factor XIIIa. (medscape.com)
Proteins1
Serine protease1
  • Plasminogen activator inhibitor-2 (placental PAI, SerpinB2, PAI-2), a serine protease inhibitor of the serpin superfamily, is a coagulation factor that inactivates tissue plasminogen activator and urokinase. (wikipedia.org)
Serpin1
Type9
Inhibits1
  • The aim of the present study was to determine whether BAY11‑7082, an inhibitor of the NF‑κB pathway, inhibits the expressions of tissue factor (TF) and plasminogen activator inhibitor‑1 (PAI‑1) in AECⅡ in response to TNF‑α. (spandidos-publications.com)
Induces1
Endothelial2
Cells2
  • Objective Cells plasminogen activator (tPA) is usually administered to acute ischemic stroke victims in a vehicle formulation containing high concentrations of L-arginine (3. (biongenex.com)
  • The effects of the overexpression of recombinant uncoupling protein 2 on proliferation, migration and plasminogen activator inhibitor 1 expression in human vascular smooth muscle cells. (cims-ops.cz)
Inhibition1
Protein6
  • This gene provides instructions for making a protein called plasminogen activator inhibitor 1 (PAI-1). (medlineplus.gov)
  • By inhibiting plasminogen activators, the PAI-1 protein helps ensure that clots remain intact until they are no longer needed to stop bleeding. (medlineplus.gov)
  • Absence of functional PAI-1 protein allows plasminogen activators to dissolve blood clots prematurely, resulting in the abnormal bleeding associated with this disorder. (medlineplus.gov)
  • Molecular genetic methods were implemented into the screening examinations for thrombophilic disorders in the 1990's along with the first discoveries of coagulation inhibitors (AT, protein C and protein S). The discovery of the molecular cause of activated protein C (APC) resistance by Bertina in 1994 greatly expanded their utilization. (intechopen.com)
  • RAF265 uPA catalyzes the transformation from the inactive zymogen plasminogen towards the energetic broad-spectrum protease plasmin which can degrade many extracellular protein eg fibrin and laminin. (tam-receptor.com)
  • 5 6 uPA-directed activation of plasminogen takes place mainly over the cell surface area after concomitant binding of uPA to its particular receptor uPAR and of plasminogen to protein with C-terminal lysines. (tam-receptor.com)
Mice2
  • 10 11 The hypothesis of a causal part of uPA-catalyzed plasminogen activation and plasmin proteolytic activity in main tumor growth local invasion and/or metastasis was recently strongly supported by studies with tumors growing on mice with targeted disruption of the uPA or plasminogen genes 3 including a study having a genetically induced mammary carcinoma. (tam-receptor.com)
  • Ho-1-deficient (Hmox1-/-) mice exhibited lethal ischemic lung injury, but were rescued from death by inhaled CO. CO drove ischemic protection by activating soluble guanylate cyclase and thereby suppressed hypoxic induction of the gene encoding plasminogen activator inhibitor-1 (PAI-1) in mononuclear phagocytes, which reduced accrual of microvascular fibrin. (nih.gov)
Alveolar1
Molecule1
  • The procoagulant molecule plasminogen activator inhibitor-1 is associated with injury severity and shock in patients with and without traumatic brain injury. (uchicago.edu)
Exogenous2
  • 12 ] Recent small clinical studies have also demonstrated potential therapeutic effects of supplementing the fibrinolytic system, where exogenous administration of tissue plasminogen activator (tPA) resulted in improvement of respiratory function and reduced mortality in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS). (thieme-connect.com)
  • Originally, rFVIIa was developed for the treatment of bleeding complications in patients with hemophilia with alloantibodies (inhibitors) against exogenous factor VIII or IX. (medscape.com)
Indications1
Platelets1
  • 6) Our in vitro aggregation studies show that platelets in the presence of the aggregation inhibitor become activated and change shape in response to platelet agonists but fail to maintain the aggregated state. (cdc.gov)
Migration1
  • Its effects on ROS production, AP-1 activity, plasminogen activator inhibitor 1 (PAI-1) gene expression, and cellular proliferation and migration were measured in response to high glucose and angiotensin II (Ang II) concentrations, two major factors in the pathogenesis of atherosclerosis in patients with diabetes and hypertension. (cims-ops.cz)
Factor2
  • Testing for inhibitors is indicated when bleeding is not controlled after infusion of adequate amounts of factor concentrate during a bleeding episode. (medscape.com)
  • Recombinant factor VIIa (rFVIIa) has become available for treating people with hemophilia with inhibitors who experience bleeding or require surgery. (medscape.com)
Intrinsic1
  • A hydrogen bond unique to Ser190 protease-arylamidine complexes between O gamma(Ser190) and the inhibitor amidine confers an intrinsic preference for such inhibitors toward Ser190 proteases over Ala190 counterparts. (rcsb.org)
Detection4
MeSH1
  • Plasminogen Activator Inhibitor 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (childrensmercy.org)
Plasma4
  • High plasma plasminogen activator inhibitor-1 (PAI-1) activity is associated with insulin resistance and is correlated with hyperinsulinemia. (jci.org)
  • Herein, we performed a prospective observational study to determine whether circulating plasma levels of plasminogen activator inhibitor-1 (PAI-1) and tPA may be significantly elevated in patients with severe COVID-19. (thieme-connect.com)
  • The presence of inhibitors is indicated by failure of correction of clotting times with 1:1 mix with normal plasma. (medscape.com)
  • ATP III recommended first-line therapy the plasma plasminogen activator inhibitor and increased physical activity. (bvsalud.org)
Stability1
  • Plasminogen activator inhibitor 1 mRNA stability was determined by transcription chase studies. (usuhs.edu)
Human1
  • Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. (jci.org)
Drugs5
Levels2
  • Moreover, levels of NF‑κB p65 (p65), phosphorylated (p)‑p65 (p‑p65), inhibitor of NF‑κB α (IκBα) and p‑IκBα were also evaluated. (spandidos-publications.com)
  • Elevated levels of plasminogen activator inhibitor-1 (PAI-1) are associated with poor prognosis in cancer. (ku.dk)
Patients2
  • [ 12 ] Recently, the effectiveness and safety of rFVIIa in patients with hemophilia with inhibitors has been reported in the hemophilia research society registry. (medscape.com)
  • At present, the only US Food and Drug Administration-approved use of rFVIIa is for the treatment of patients with hemophilia with inhibitors. (medscape.com)
Potential1
  • In experimental studies a potential role of plasminogen activator inhibitor-1 (PAI-1) in bone remodeling is suggested but studies in humans are lacking. (kbco.hr)
Publications2
  • This graph shows the total number of publications written about "Plasminogen Activator Inhibitor 2" by people in this website by year, and whether "Plasminogen Activator Inhibitor 2" was a major or minor topic of these publications. (childrensmercy.org)
  • Below are the most recent publications written about "Plasminogen Activator Inhibitor 2" by people in Profiles. (childrensmercy.org)